Item 5. Other Information
Item
5. Other Information.
None.
Item
6. Exhibits
The
following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q.
No.
Description
of Exhibit
1.1
Underwriting
Agreement, dated October 26, 2021, by and between the Company and I-Bankers Securities, Inc., as representative of the several underwriters
(incorporated by reference to Exhibit 1.1 to the Company’s Current Report on Form 8-K filed with the Commission on November
1, 2021).
1.2
Business
Combination Marketing Agreement, dated October 26, 2021, by and between the Company and I-Bankers Securities, Inc. (incorporated
by reference to Exhibit 1.2 to the Company’s Current Report on Form 8-K filed with the Commission on November 1, 2021).
2.1*
Business
Combination Agreement dated July 12, 2022, among Deep Medicine Acquisition Corp., Chijet Inc., Chijet Motor Company, Inc., Chijet
Motor (USA) Company, Inc. and the Sellers named therein (incorporated by reference to Exhibit 2.1 to the Company’s Current
Report on Form 8-K filed with the Commission on July 18, 2022).
3.1
Certificate
of Correction to the Second Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Company’s
Current Report on Form 8-K filed with the Commission on November 4, 2021).
3.2
Bylaws
(incorporated by reference to Exhibit 3.3 to the Company’s Registration Statement on Form S-1 (File No. 333-259500) filed with
the Commission on September 13, 2021).
4.1
Rights
Agreement, dated October 26, 2021, by and between the Company and American Stock Transfer & Trust Company, LLC, as rights agent
(incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed with the Commission on November
1, 2021).
22
10.1
Letter
Agreement, dated October 26, 2021, by and among the Company, its officers, its directors, Bright Vision Sponsor LLC and I-Bankers
Securities, Inc. (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the Commission
on November 1, 2021).
10.2
Investment
Management Trust Agreement, dated October 26, 2021, by and between the Company and American Stock Transfer & Trust Company, LLC,
as trustee. (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed with the Commission
on November 1, 2021).
10.3
Registration
Rights Agreement, dated October 26, 2021, by and among the Company and certain security holders. (incorporated by reference to Exhibit
10.3 to the Company’s Current Report on Form 8-K filed with the Commission on November 1, 2021).
10.4
Private
Placement Units Purchase Agreement, dated October 26, 2021, by and among the Company, Bright Vision Sponsor LLC and I-Bankers Securities,
Inc. (incorporated by reference to Exhibit 10.4 to the Company’s Current Report on Form 8-K filed with the Commission on November
1, 2021).
10.4
Support
Agreement dated July 12, 2022, among Deep Medicine Acquisition Corp., Bright Vision Sponsor LLC, Chijet Inc. and Chijet Motor Company,
Inc. (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the Commission on July
18, 2022).
10.5
Form
of Lock-Up Agreement (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed with the
Commission on July 18, 2022).
10.6
Form
of Amended and Restated Registration Rights Agreement (incorporated by reference to Exhibit 10.3 to the Company’s Current Report
on Form 8-K filed with the Commission on July 18, 2022).
31.1**
Certification
of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section
302 of the Sarbanes-Oxley Act of 2002
31.2**
Certification
of Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section
302 of the Sarbanes-Oxley Act of 2002
32.1***
Certification
of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of
2002
32.2***
Certification
of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of
2002
101.INS**
Inline
XBRL Instance Document
101.SCH**
Inline
XBRL Taxonomy Extension Schema Document
101.CAL**
Inline
XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF**
Inline
XBRL Taxonomy Extension Definition Linkbase Document
101.LAB**
Inline
XBRL Taxonomy Extension Labels Linkbase Document
101.PRE**
Inline
XBRL Taxonomy Extension Presentation Linkbase Document
104**
Cover
Page Interactive Data File.
*
Certain
of the exhibits, appendices, annexes and/or schedules to this Exhibit have been omitted in accordance with Regulation S-K Item 601(b)(2).
The Registrant agrees to furnish supplementally a copy of all omitted exhibits, annexes, appendices and schedules to the Securities
and Exchange Commission upon its request.
**
Filed
herewith.
***
Furnished
herewith.
23
SIGNATURES
In
accordance with the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
DEEP
MEDICINE ACQUISITION CORP.
Date:
August 3, 2022
By:
/s/
Humphrey P. Polanen
Name:
Humphrey
P. Polanen
Title:
Chief
Executive Officer
(Principal
Executive Officer)
Date:
August 3, 2022
By:
/s/
Weixuan Luo
Name:
Weixuan
Luo
Title:
Chief
Financial Officer
(Principal
Financial and Accounting Officer)
24
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.